Poolbeg Pharma (POLB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

9.85p
   
  • Change Today:
      0.20p
  • 52 Week High: 11.50
  • 52 Week Low: 6.55
  • Currency: UK Pounds
  • Shares Issued: 500.00m
  • Volume: 1,325,502
  • Market Cap: £49.25m

Poolbeg identifies new drug candidates with OneThree

By Josh White

Date: Wednesday 21 Dec 2022

LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.
The AIM-traded firm said that since initiating the collaboration in February, its scientific team had worked closely with OneThree to build a tailored AI approach that leverages its "unique" RSV human challenge trial data to identify disease-relevant biological pathways and potential drug targets.

Based on those newly-discovered drug targets, the collaboration had now identified a number of "promising" drug candidates to bring forward to lab-based validation to determine the full potential of these assets.

The company said it had prioritised compounds with existing phase 1 clinical data, and which could, if successfully validated, be repositioned as novel treatments for RSV infection.

Candidates with solid safety and pharmacodynamic data in humans were "well-positioned" to rapidly enter a clinical trial to generate early human efficacy data for RSV, the board explained.

That was in line with Poolbeg's efficient, capital light clinical development strategy that is at the core of its ambitious growth model.

"In the past few months, RSV has been sending children to hospital at alarming rates in the US and Europe," said chief executive officer Jeremy Skillington.

"As paediatric units fill beyond capacity, and our healthcare systems contend with a 'tripledemic' of RSV, influenza and SARS-CoV-2, the need for better treatments has never been so urgent.

"We're impressed with the quality of work executed so far with OneThree leveraging their AI expertise to present new drug potential candidates from our unique human challenge trial data which Poolbeg will now optimise for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited."

At 1312 GMT, shares in Poolbeg Pharma were up 1.24% at 6.12p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Poolbeg Pharma Market Data

Currency UK Pounds
Share Price 9.85p
Change Today 0.20p
% Change 2.07 %
52 Week High 11.50
52 Week Low 6.55
Volume 1,325,502
Shares Issued 500.00m
Market Cap £49.25m

Poolbeg Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
59.26% below the market average59.26% below the market average59.26% below the market average59.26% below the market average59.26% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Price Trend
92.00% above the market average92.00% above the market average92.00% above the market average92.00% above the market average92.00% above the market average
96.49% above the sector average96.49% above the sector average96.49% above the sector average96.49% above the sector average96.49% above the sector average
Income Not Available
Growth Not Available

Poolbeg Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:26 50,000 @ 9.80p
16:22 25,090 @ 10.00p
16:16 5,953 @ 9.95p
16:14 15 @ 9.62p
16:12 10,000 @ 9.74p

Poolbeg Pharma Key Personnel

CEO Jeremy Skillington
CFO Ian O’Connel

Top of Page